|
1
|
Alberg AJ, Ford JG and Samet JM: American
College of Chest Physicians: Epidemiology of lung cancer: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest.
132:(3 Suppl). 29S–55S. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baltayiannis N, Chandrinos M,
Anagnostopoulos D, Zarogoulidis P, Tsakiridis K, Mpakas A,
Machairiotis N, Katsikogiannis N, Kougioumtzi I, Courcoutsakis N
and Zarogoulidis K: Lung cancer surgery: An up to date. J Thorac
Dis. 5:(Suppl 4). S425–S439. 2013.PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wingo PA, Cardinez CJ, Landis SH, Greenlee
RT, Ries LA, Anderson RN and Thun MJ: Long-term trends in cancer
mortality in the United States, 1930–1998. Cancer. 97:(12 Suppl).
S3133–S3275. 2003. View Article : Google Scholar
|
|
5
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Davies J, Patel M, Gridelli C, de Marinis
F, Waterkamp D and McCusker ME: Real-world treatment patterns for
patients receiving second-line and third-line treatment for
advanced non-small cell lung cancer: A systematic review of
recently published studies. PLoS One. 12:e01756792017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoon SM, Shaikh T and Hallman M:
Therapeutic management options for stage III non-small cell lung
cancer. World J Clin Oncol. 8:1–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galvani E, Peters GJ and Giovannetti E:
EGF receptor-targeted therapy in non-small-cell lung cancer: Role
of germline polymorphisms in outcome and toxicity. Future Oncol.
8:1015–1029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bach DH, Hong JY, Park HJ and Lee SK: The
role of exosomes and miRNAs in drug-resistance of cancer cells. Int
J Cancer. 141:220–230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borst P, Evers R, Kool M and Wijnholds J:
A family of drug transporters: The multidrug resistance-associated
proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allen JD and Schinkel AH: Multidrug
resistance and pharmacological protection mediated by the breast
cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther. 1:427–434.
2002.PubMed/NCBI
|
|
12
|
Oshikata A, Matsushita T and Ueoka R:
Enhancement of drug efflux activity via MDR1 protein by spheroid
culture of human hepatic cancer cells. J Biosci Bioeng.
111:590–593. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Joyce H, McCann A, Clynes M and Larkin A:
Influence of multidrug resistance and drug transport proteins on
chemotherapy drug metabolism. Exp Opin Drug Metab Toxicol.
11:795–809. 2015. View Article : Google Scholar
|
|
14
|
El-Sheikh AA, Morsy MA, Mahmoud MM and
Rifaai RA: Protective mechanisms of coenzyme-Q10 may involve
up-regulation of testicular P-glycoprotein in doxorubicin-induced
toxicity. Environ Toxicol Pharmacol. 37:772–781. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ponnusamy L, Mahalingaiah PKS and Singh
KP: Treatment schedule and estrogen receptor-status influence
acquisition of doxorubicin resistance in breast cancer cells. Eur J
Pharm Sci. 104:424–433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang CY, Bai XY and Wang CH: Traditional
chinese medicine: A treasured natural resource of anticancer drug
research and development. Am J Chin Med. 42:543–559. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Z, Chen S, Cai J, Zhang E, Lan L,
Zheng J, Liao L, Yang X, Zhou C and Du J: Traditional Chinese
medicine syndrome-related herbal prescriptions in treatment of
malignant tumors. J Tradit Chin Med. 33:19–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo
J and Hu X: Shikonin circumvents cancer drug resistance by
induction of a necroptotic death. Mol Cancer Ther. 6:1641–1649.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang H, Zhou P, Huang H, Chen D, Ma N, Cui
QC, Shen S, Dong W, Zhang X, Lian W, et al: Shikonin exerts
antitumor activity via proteasome inhibition and cell death
induction in vitro and in vivo. Int J Cancer. 124:2450–2459. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xuan Y and Hu X: Naturally-occurring
shikonin analogues-a class of necroptotic inducers that circumvent
cancer drug resistance. Cancer Lett. 274:233–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bailly C: Topoisomerase I poisons and
suppressors as anticancer drugs. Curr Med Chem. 7:39–58. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakaya K and Miyasaka T: A shikonin
derivative, beta-hydroxyisovalerylshikonin, is an
ATP-non-competitive inhibitor of protein tyrosine kinases.
Anticancer Drugs. 14:683–693. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim SH, Kang IC, Yoon TJ, Park YM, Kang
KS, Song GY and Ahn BZ: Antitumor activities of a newly synthesized
shikonin derivative, 2-hyim-DMNQ-S-33. Cancer Lett. 172:171–175.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang IC, Huang YJ, Chiang TI, Yeh CW and
Hsu LS: Shikonin induces apoptosis through reactive oxygen
species/extracellular signal-regulated kinase pathway in
osteosarcoma cells. Biol Pharm Bull. 33:816–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Long S, GuangZhi Y, BaoJie G, Wei X,
YanYong H, YingLi W, Yang Z and LiHua L: Shikonin derivatives
protect immune organs from damage and promote immune responses in
vivo in tumour-bearing mice. Phytother Res. 26:26–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu H, Xie J, Pan Q, Wang B, Hu D and Hu X:
Anticancer agent shikonin is an incompetent inducer of cancer drug
resistance. PLoS One. 8:e527062013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
EI Sayed SM, Mahmoud AA, EI Sawy SA,
Abdelaal EA, Fouad AM, Yousif RS, Hashim MS, Hemdan SB, Kadry ZM,
Abdelmoaty MA, et al: Warburg effect increases steady-state ROS
condition in cancer cells through decreasing their antioxidant
capacities (anticancer effects of 3-bromopyruvate through
antagonizing Warburg effect). Med Hypotheses. 81:866–870. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carraro M and Bernardi P: Calcium and
reactive oxygen species in regulation of the mitochondrial
permeability transition and of programmed cell death in yeast. Cell
Calcium. 60:102–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Padmapriya R, Gayathri L, Ronsard L,
Akbarsha MA and Raveendran R: In vitro anti-proliferative effect of
tephrosia purpurea on human hepatocellular carcinoma cells.
Pharmacogn Mag. 13:(Suppl 1). S16–S21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Falasca M and Linton KJ: Investigational
ABC transporter inhibitors. Expert Opin Invest Drugs. 21:657–666.
2012. View Article : Google Scholar
|
|
31
|
Joyce H, McCann A, Clynes M and Larkin A:
Influence of multidrug resistance and drug transport proteins on
chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol.
11:795–809. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kathawala RJ, Gupta P, Ashby CR Jr and
Chen ZS: The modulation of ABC transporter-mediated multidrug
resistance in cancer: A review of the past decade. Drug Resist
Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pavan B, Paganetto G, Rossi D and Dalpiaz
A: Multidrug resistance in cancer or inefficacy of neuroactive
agents: Innovative strategies to inhibit or circumvent the active
efflux transporters selectively. Drug Discov Today. 19:1563–1571.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ponisovskiy MR: Warburg effect mechanism
as the target for theoretical substantiation of a new potential
cancer treatment. Crit Rev Eukaryot Gene Expr. 21:13–28. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bayley JP and Devilee P: The Warburg
effect in 2012. Curr Opin Oncol. 24:62–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg's contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sotgia F, Martinez-Outschoorn UE and
Lisanti MP: Genetic induction of the Warburg effect inhibits tumor
growth. Oncotarget. 3:1266–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Granchi C and Minutolo F: Anticancer
agents that counteract tumor glycolysis. ChemMedChem. 7:1318–1350.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Park S, Shimizu C, Shimoyama T, Takeda M,
Ando M, Kohno T, Katsumata N, Kang YK, Nishio K and Fujiwara Y:
Gene expression profiling of ATP-binding cassette (ABC)
transporters as a predictor of the pathologic response to
neoadjuvant chemotherapy in breast cancer patients. Breast Cancer
Res Treat. 99:9–17. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kovalev AA, Tsvetaeva DA and Grudinskaja
TV: Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the
development of primary and acquired multiple drug resistance in
patients with early and metastatic breast cancer. Exp Oncol.
35:287–290. 2013.PubMed/NCBI
|
|
42
|
Hou X, Huang F, Carboni JM, Flatten K,
Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis
MM, et al: Drug efflux by breast cancer resistance protein is a
mechanism of resistance to the benzimidazole insulin-like growth
factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer
Ther. 10:117–125. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nambaru PK, Hübner T, Köck K, Mews S,
Grube M, Payen L, Guitton J, Sendler M, Jedlitschky G, Rimmbach C,
et al: Drug efflux transporter multidrug resistance-associated
protein 5 affects sensitivity of pancreatic cancer cell lines to
the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos.
39:132–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schinkel AH and Jonker JW: Mammalian drug
efflux transporters of the ATP binding cassette (ABC) family: An
overview. Adv Drug Deliv Rev. 55:3–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao H, Lamusta J, Zhang WF, Salmonsen R,
Liu Y, O'Connell E, Evans JE, Burstein S and Chen JJ: Tumor cell
selective cytotoxicity and apoptosis induction by an herbal
preparation from Brucea javanica. N Am J Med Sci (Boston). 4:62–66.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yeh YC, Liu TJ and Lai HC: Shikonin
induces apoptosis, necrosis, and premature senescence of human A549
lung cancer cells through upregulation of p53 expression. Evid
Based Complement Alternat Med. 2015:6203832015. View Article : Google Scholar : PubMed/NCBI
|
